Related Experiment Video
Updated: Dec 10, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Intravitreal slow-releasing dexamethasone implant for idiopathic neuroretinitis
Osman Çekiç1, Samet Gülkaş1,2
1Department of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey.
Introduction:
The purpose of this report is to describe a successful management of idiopathic neuroretinitis with intravitreal dexamethasone implant.
Method:
Interventional case report.
Clinical Case:
A 34-year-old man with an acute painless unilateral vision loss, optic disc swelling, and a macular edema was diagnosed as idiopathic neuroretinitis, and he underwent 0.7 mg dexamethasone intravitreous implant injection. Macular edema responded quickly and visual acuity improved from 20/50 to 20/25 within 2 weeks and to 20/20 within a month. One month after the injection, optic disc edema disappeared. No recurrence occurred and visual acuity was stable at 20/20 during 3 years of follow-up.
Conclusion:
Idiopathic neuroretinitis can be treated with intravitreal dexamethasone implant.
More Related Videos
07:49Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment